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Summary The phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA) (10 nM) produced a marked reduc-
tion in the growth, measured by thymidine uptake, of MCF-7 cells in full growth medium, but had only a
small effect on MDA-MB-231 and T47D cells. Bryostatin alone also inhibited growth but to a lesser extent
than seen with TPA. The effect of TPA on MCF-7 cells was partially reversed by bryostatin, added
simultaneously or after TPA, suggesting bryostatin does not simply mimic TPA in this sytem. Even though
both are believed to act via effects on protein kinase C, bryostatin appears to act as an antagonist to the effect
of TPA as well as a partial agonist on its own. When the oestrogen receptor positive MCF-7 and T47D cells
were maintained in charcoal stripped serum, the increase in DNA synthesis on stimulation with oestradiol was
inhibited with 50 nm TPA in MCF-7 cells but not in T47D cells.
The effects of these treatments on the expression of two well characterised oestrogen responsive genes
pNR2(pS2) and pNRIOO (Cathepsin-D) were examined. Rather than preventing transcription of these oest-
rogen responsive genes, TPA alone increased pNR2 and pNR100 levels in MCF-7 cells and the combined
effect of oestradiol and TPA had a marked synergistic effect in increasing the transcript levels of these genes.
In T47D cells pNR2 transcripts were not detected and the increase in pNRIO0 mRNA levels were not affected
by TPA. We conclude that the inhibitory effects of TPA on the growth stimulation of MCF-7 cells by
oestradiol was not due to a general inhibition of the expression of oestrogen responsive genes.
An alternative possibility examined was that the growth inhibitory effect of TPA on MCF-7 cells might be
due to stimulation ofTGF-p1, acting as an autocrine inhibitory growth factor. Oestradiol treatment of MCF-7
cells reduced the levels of TGF-131 mRNA whereas TPA produced a marked increase. The combined effect of
TPA and oestradiol further increased TGF-Pl mRNA above the levels seen with TPA alone. Bryostatin had
little effect on TGF-P1 expression either alone or in combination with oestradiol. These observations are
consistent with the hypothesis that the inhibitory effect ofTPA on MCF-7 cells may be partly due to autocrine
inhibition by TGF-l.
The bryostatins are a group of macrocyclic lactones with
antineoplastic activities isolated from marine bryozoans (Pet-
tit et al., 1970). The bryostatins have been shown to bind to
and activate the calcium phospholipid dependent protein
kinase C in a manner similar to phorbol esters, and to block
phorbol ester binding (Smith et al., 1985; Berkow et al.,
1985). They may have a role to play in the treatment of
tumours.
The effects of bryostatins have been studied in several cell
systems in vitro, and in some systems they mimic the effects
of phorbol ester while in others they appear to have
antagonistic effects. The bryostatins, like phorbol esters, have
been shown to act as mitogens in Swiss 3T3 cells (Smith et
al., 1985), induce superoxide production in human poly-
morphonuclear leucocytes (Berkow et al., 1985), stimulate
prolactin synthesis in GH4C5 rat pituitary cells (Ramsdell et
al., 1986), promote soft agar growth of JB6 mouse epidermal
cells (Kraft et al., 1988) and inhibit cell coupling in mouse
epidermal cells (Pasti et al., 1988). In A549 human lung
carcinoma cells (Dale & Gescher, 1989) bryostatin arrested
cell growth in a similar manner to phorbol esters, but at
higher concentrations abolished the inhibitory effect of TPA
on growth.
In other systems, the bryostatins have been shown to
inhibit phorbol ester induced responses or have an antagonist
effect to phorbol esters. Unlike TPA, bryostatin is unable to
induce differentiation in the human promyelocytic cell line
HL60 (Kraft et al., 1986) although varying responses to
bryostatin have been shown in four HL60 sublines (Kraft et
al., 1989) and in a human colon cancer cell line (VOM),
bryostatin counteracts the effect of TPA in inducing rapid
terminal differentiation (McBain et al., 1988). Bryostatin
blocked phorbol ester induced arachidonic acid metabolite
release in mouse fibroblast cells (Dell'Aquila et al., 1988) and
had a differing effect on EGF binding in these cells. The
inhibition of epidermal growth factor (EGF) binding to
mouse epidermal cells with phorbol esters was abolished by
the addition of bryostatin, although in some reactions in this
cell line, bryostatin mimicked the effect of phorbol esters
(Sako et al., 1987). Bryostatin also antagonises the induction
of squamous differentiation in tracheobronchial epithelial
cells by phorbol esters (Jetten et al., 1989).
The phorbol esters act as tumour promoters in vivo and
stimulate the growth of a wide range of non-transformed
cells in vitro, but also are found to be growth inhibitory for
some transformed cells, suggesting protein kinase C acti-
vators may have a therapeutic role depending on tumour
type. 12-O-tetradecanoylphorbol-13-acetate (TPA) is the
phorbol ester with the greatest potency as a tumour pro-
moter. To investigate the characteristics of transformed cells
which render them susceptible to growth inhibition by pro-
tein kinase C activators we have studied the effects of both
TPA and bryostatin-2 on three human breast cell lines with
differing responses to oestradiol and EGF. The oestrogen
receptor positive cell lines MCF-7 and T47D, and the oestro-
gen receptor negative cell line MDA-MB-231 were used. TPA
was found to inhibit the stimulation of growth by oestradiol
only in MCF-7 cells. In order to investigate the mechanisms
of this response, the effect of TPA and bryostatin on the
transcription of oestrogen-responsive genes and TGF-1I was
studied.
Materials and methods
Routine cell culture
All cell lines were maintained in Eagle MEM containing 10%
foetal calf serum, 20 mM glutamine, 2 g -' sodium bicar-
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bonate, 1 mM sodium pyruvate, 100 U ml-' penicillin and
0.1 mgml1 streptomycin. Routine cultures were grown in
25 cm2 tissue culture flasks, and subcultured weekly using
0.25% Trypsin + 0.2% EDTA in DulA. Cultures were
checked at monthly intervals to ensure they were free from
mycoplasma contamination. Cultures were maintained at
37°C in a humidified incubator gassed with 95% air, 5%
CO2.
Oestradiol stimulation
In experiments where oestradiol stimulation was studied, cells
were seeded into 96 well plates in phenol red free medium
(Flow Autopow) containing 10% dextran coated charcoal
treated foetal calf serum. Cells were maintained in this
medium for 4 days before test medium was added.
3H-thymidine uptake
Cells were seeded into 96 well plates using 0.2 ml medium per
well. After 48 h the medium was removed and replaced with
test medium for a further 48 h. Where mixtures of TPA and
bryostatin were used, the medium containing the required
concentrations was prepared before addition of the medium
to the cells. The test medium was removed, cells washed with
PBS and 3H-thymidine (100 nM) in serum-free medium added
for 2 h. The cells were washed after removal of the radio-
active medium, solubilised in 0.5 M sodium hydroxide and
the DNA collected onto filters by means of a Titretek cell
harvester. The filters were counted for radioactivity using an
LKB liquid scintillation counter. Control incubations were
used in each assay and results expressed as thymidine uptake
as a percentage of controls. Six replica determinations were
carried out for each point and the mean and associated SEM
plotted. In preliminary experiments we had established that
uptake of 3H-thymidine correlates well with cell number.
mRNA levels ofoestrogen-responsive genes
MCF-7 cells were depleted of oestrogens using the method of
May and Westley (1988), by using phenol red free medium
containing 10% FBS treated with dextran coated charcoal,
for 6 days. Large petri dishes were used for the cells, and
after 24 h of treatment with oestradiol alone or in combina-
tion with TPA or bryostatin, RNA was prepared by the
RNAzol method (Chomczynski & Sacchi, 1987). Northern
blot hybridisation was used to measure the mRNA levels for
the oestrogen responsive genes pNR100 (Cathepsin-D) and
pNR2 (pS2) (May & Westley, 1986). The pNR2 and pNR100
probes were labelled by the random primer extension method
(Feinberg & Vogelstein, 1983). Standard Northern blot hy-
bridisation procedures using the glyoxal method were em-
ployed, as described elsewhere (Mason & Williams, 1985).
For all Northern blots gels were stained with ethidium
bromide prior to transfer to nylon membranes in order to
check equal loading. Subsequent reprobing of filters with an
18S ribosomal RNA probe was used to verify loading and
transfer.
TGF-PI expression
Northern blot hybridisation was also used to measure TGF-
P1 mRNA levels in cells treated with combinations of
oestradiol, TPA and bryostatin, under conditions described
for oestrogen genes above. The hybridisation probe used was
an insert preparation from a TGF-P1 cDNA clone supplied
by Dr Rik Derynck, Genentech (Derynck et al., 1985).
Results
Effects of TPA andbryostatin on 3H-thymidine uptake
The effects of TPA, bryostatin and equimolar mixtures of
TPA and bryostatin differed in the three cell lines tested, as
shown (Figure la,b,c). MDA cells showed a 30% decrease in
thymidine uptake with both TPA and bryostatin and
equimolar concentrations of both. No reduction in
3H-thymidine uptake was found in the T47D cells after 48 h
with either of these agents, and when this test incubation was
extended to 5 days no effect was again found. Bryostatin had
a significant growth inhibitory effect on MCF-7 cells, with
uptake of 3H-thymidine reduced to 70% of control with
100 nM bryostatin. However, a more pronounced reduction
to less than 10% of control was seen with 10 nM TPA. This
reduction of thymidine uptake with TPA was partially
reversed by the use of equimolar concentrations of bryo-
statin. With 1OnM TPA growth inhibition was reduced to
6.3 ± 0.7% (n = 6) of control, whereas with 10 nM TPA plus
10 nM bryostatin the growth inhibition was reduced to only
30 ± 4% (n = 6) of control. This difference was statistically
significant (P <0.05).
The antagonistic effect of byrostatin on the response of
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Figure 1 a-c, Effect of increasing concentrations of TPA and
bryostatin on the growth of three breast cell lines: A TPA, 0
Bryostatin, 0 Equimolar concentrations of TPA and bryostatin,
d, Effect of 50nM TPA (A) and 50nM TPA with increasing
concentrations of bryostatin (0) on the growth of MCF-7 cells.
Seeding densities were MDA7 x 103 cells/well, T47D and MCF-7
2 x I04cells/well. Results are expressed as a percentage of 3H-
thymidine uptake in controls grown in normal medium. Each
point is the mean of n = 6 results±SEM in one experiment in
this and subsequent graphs.
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MCF-7 cells to TPA was further studied by increasing the
concentration of byrostatin with a fixed concentration of
50 nM TPA using 48 h incubations (Figure Id). With increas-
ing concentrations of bryostatin, the 3H-thymidine uptake was
increased but the effect of 50 nM TPA could not be complete-
ly overcome even with 1 gM bryostatin.
The growth inhibitory effect of TPA on MCF-7 cells
remained at the same level with increasing concentrations
from l0nM to 1 gM with 48 h incubation. The time course of
the effect of 50 nM TPA on MCF-7 cells was investigated by
varying the time of treatment of cells with TPA from 48 h to
2 h before labelled thymidine was added. The results are
shown in Figure 2. The thymidine uptake was reduced by
50% with 4 h incubation with TPA, and maximum reduction
to 7 % was achieved after 18 h treatment.
Since incubation with bryostatin partially reversed the
growth inhibitory effect ofTPA on MCF-7 cells, the effect of
TPA treatment time before addition of bryostatin was in-
vestigated. Cells were treated with 50 nM TPA for 2 to 6 h,
after which time the cells were washed before addition of
control medium or medium containing bryostatin for the
remainder of the 48 h incubation. The results are shown in
Figure 3. After 6 h incubation with TPA, bryostatin was still
able to partially reverse the effect of the TPA on 3H-thymidine
uptake.
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Figure 2 The effect of time of treatment with 50 nM TPA on
MCF-7 cell growth measured by 3H-thymidine uptake relative to
control cells in normal growth medium.
Inhibition ofoestradiol stimulation by TPA andbryostatin
The combined effect of TPA and bryostatin on growth
stimulation by oestradiol was studied in the oestrogen recep-
tor positive cell lines MCF-7 and T47D. After depleting cells
of oestradiol by incubation in oestrogen-depleted medium for
4 days, cells were treated with a range of oestradiol concen-
trations for 3 days and the effect on growth measured using
3H-thymidine uptake. The effects of 50 nM TPA and 100 nM
bryostatin on growth stimulation by 0.1 nM oestradiol was
measured. The results obtained are shown in Figure 4. In the
T47D cell line, oestradiol greatly increased the thymidine
uptake of the cells whereas in the MCF-7 cells 0.1 nM oest-
radiol only doubled the thymidine uptake compared to the
control. In depleted medium and the absence of oestradiol
both TPA and bryostatin stimulated the uptake of 3H-thymi-
dine into T47D cells, and had no influence on the growth
stimulatory effect of oestradiol on these cells. In contrast, in
the MCF-7 cell line, in addition to having growth inhibitory
effects alone, TPA prevented the growth stimulation by oest-
radiol. The oestradiol stimulation of growth was not
influenced by the presence of bryostatin alone but bryostatin
partially antagonised the effects of TPA on oestradiol
stimulated growth. In the presence of TPA 3Hthymidine
uptake in MCF-7 cells remained at less than 10% of control
when oestradiol was added. However, when bryostatin was
included with TPA the 3H-thymidine uptake was only reduced
to 80% of control.
The effects of TPA andbryostatin on the transcription of
oestrogen responsive genes
Cells depleted of oestradiol were stimulated for 24h with
oestradiol, TPA or bryostatin or mixtures of oestradiol and
TPA or bryostatin. The effect on mRNA levels of the
oestrogen-responsive genes pNR2 and pNRIOO was investi-
gated (Figures 5 and 6). In MCF-7 cells both oestradiol and
TPA increased pNR2 mRNA. Bryostatin alone had no effect.
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Figure 3 Effect of 100 nM bryostatin on MCF-7 cell growth
following initial incubation with 50 nm TPA. Cross-hatched
columns T: 50 nM TPA, B: 100 nM bryostatin for 48 h. White
columns: 50 nM TPA replaced by normal medium after time
shown; black columns: 50 nM TPA replaced by medium contain-
ing 100 nM bryostatin after time shown. Growth is measured as
3H-thymidine uptake relative to control cells in normal growth
medium.
Figure 4 Effect of oestradiol, TPA and bryostatin on the growth
of T47D and MCF-7 cells, measured by thymidine uptake. Cells
were depleted of oestradiol for 4 days before addition of medium
containing stripped FBS and oestradiol (cross-hatched blocks) in
concentrations 1: 0.01 nM; 2: 0.1 nM; 3: 1 nM; 4: 10 nm. N: addi-
tion of medium containing 10% untreated FBS. T: 50 nM TPA;
B: 100 nM bryostatin in the absence (white columns) or presence
(black columns) of0.1 nM oestradiol. Control refers to the uptake
of thymidine in medium containing charcoal-stripped serum.
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Figure 5 Northern blot hybridisation of MCF-7 cell RNA with
pNR2, pNR100 and 18S rRNA. Treatment of cells: C: control;
E: 0.1 nM oestradiol; 50 nM TPA; B: 100 nM bryostatin.
C E T T B B
E E
M
pNR100-
j2.:
pNR2- .:
Effect on the expression ofTGF-PI
The RNA prepared after treatment of cells with oestradiol,
TPA or bryostatin was also probed for TGF-p1. In MCF-7
cells, a reduction in TGF-PI expression was found with
oestradiol treatment (Figure 7), whereas TPA produced a
marked increase. The combination of TPA and oestradiol
further increased TGF-P1 mRNA levels above those with
TPA alone. Bryostatin had little effect on TGF-P1 expression
either alone or in combination with oestradiol. TGF-P1 ex-
pression was not detected in T47D cells.
Discussion
The effect of the tumour promoter TPA in the MCF-7 breast
cell line has been widely studied, but the effect of TPA on
breast cell lines in relation to their hormonal responses is still
not clearly understood. In MCF-7 cells, TPA causes growth
arrest, which is reversible by removal of TPA, and also
changes in cell morphology (Osborne et al., 1981). Cell
division was prevented with TPA and an increase in the
protein: DNA ratio obtained. Our studies with TPA and
MCF-7 cells have shown similar results and the effect ofTPA
can be partially reversed, not only by removing the TPA but
also by the addition of bryostatin, which also binds to pro-
tein kinase C.
The growth inhibitory effect of TPA is thought to be
mediated by binding to protein kinase C. However, the effect
of TPA varied in the three cell lines studied in a manner
which did not correlate with either the oestrogen receptor
status or the reported protein kinase C concentration in these
cells (Borner et al., 1988; Fabbro et al., 1986), where ER
negative cells displayed higher amounts of protein kinase C
compared to ER positive cell lines: MDA> MCF-7> T47D.
The relatively low amount of protein kinase C in T47D cells
may explain the lack of any effect of TPA or bryostatin on
growth or pNRIOO mRNA in these cells compared with
MCF-7 cells. A rapid decrease in cytosolic protein kinase C
after TPA treatment of MCF-7 cells has been described
(Issandou et al., 1986) and subsequently it was shown that
only 10% of initial protein kinase C activity remains in
MCF-7 cells after 48 h of TPA treatment (Issandou et al.,
1988). The rapid translocation of protein kinase C activity
from the cytosolic to particulate fractions of the cell and the
rapid decrease in phorbol ester binding capacity at the mem-
brane level suggest a down-regulation of protein kinase C in
response to TPA treatment (Darbon et al., 1987). However
the role of protein kinase C downregulation in the growth
inhibitory effect of TPA is not clear.
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Figure 6 Northern blot hybridisation of T47D cell RNA with
pNR2, pNR100 and 18S rRNA. Treatment of cells as Figure 6.
M: RNA sample from MCF-7 cells.
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The combination of oestradiol with bryostatin increased
pNR2 mRNA but not to a greater extent than seen with
oestradiol alone. However, the combined effect of oestradiol
and TPA had a marked synergistic effect in increasing the
mRNA level of pNR2 (Figure 5). With pNRIOO, an in-
creased signal was obtained with TPA, oestradiol and bryo-
statin. A synergistic effect was obtained with the combination
of TPA and oestradiol. Also, in contrast to the lack of effect
on pNR2, bryostatin had a synergistic effect on pNRIOO
mRNA when combined with oestradiol (Figure 5).
With T47D cells, no pNR2 transcripts were detected, and
an increase in pNRIOO was only found with oestradiol
(Figure 6). Neither TPA nor bryostatin significantly altered
pNRIOO mRNA levels whether present alone or combined
with oestradiol.
18 S-
Figure 7 TGF-PI mRNA detection in MCF-7 cell RNA, show-
ing also the result of control 18S rRNA reprobing. Treatment of
cells as Figure 6.TPA AND BRYOSTATIN EFFECTS ON BREAST TUMOUR CELLS 675
The interaction between oestradiol and TPA was studied in
the hormone-sensitive cell lines. In the T47D cell line, the
oestrogen-induced growth response was unaffected by both
TPA and bryostatin. In the MCF-7 cell line, the oestrogen
response was blocked by TPA. These results are in agreement
with those of Valette et al. (1987), who has shown that TPA
blocks the increase in S phase cells induced by oestradiol. To
investigate whether TPA has a direct effect on the action of
oestradiol in the MCF-7 cells, we studied the effect of TPA
and oestradiol on mRNA levels for the oestrogen-inducible
genes pNR2(pS2) and pNR100(Cathepsin D). Our results
show that the inhibitory effects of TPA on growth stimula-
tion by oestradiol was not attributable to any general inhib-
tion of the transcription of oestrogen responsive genes. On
the contrary, treatment of MCF-7 cells with TPA or bryo-
statin lead to marked increases in the mRNA levels of the
two oestrogen responsive genes examined, beyond that
achieved with either agent alone.
It has recently been shown that, in addition to stimulation
by oestradiol, pNR2(pS2) and pNR100(Cathepsin D) are
induced in MCF-7 cells by other growth factors such as
IGF1, EGF and FGF (Cavailles et al., 1989). An increase in
pNR2 but not pNR100 mRNA in response to TPA treat-
ment was also reported. In our experiments mRNA levels for
both of these oestrogen-responsive genes were increased by
TPA treatment. The 5' regulatory sequence of the pS2 gene
has been described (Jeltsch et al., 1987). Although the
authors did not address themselves to this question, inspec-
tion of the sequence reveals the presence of two putative
TPA responsive elements, TCTCTCAC at -348 and
TGTCTCAG at -100 relative to the transcriptional start site,
which match the defined consensus sequence (Angel et al.,
1987). The presence of these elements is consistent with the
observed effect of TPA on pNR2 mRNA levels. Further
studies are required to establish if these putative TPA re-
sponse elements are functional and whether direct transcrip-
tional regulation of the pNR2 gene is involved. At present
there is no information available on the regulatory sequences
of the pNR100 gene.
The synergistic effect of combined TPA and oestradiol on
transcript levels of oestrogen-responsive genes has not been
previously reported. Whether the mechanism for this
operates at the transcriptional level or whether de novo
protein synthesis is required remains to be established. How-
ever, such an effect could conceivably result from an increase
in protein kinase C levels in response to oestradiol or an
increase in oestradiol receptors in response to TPA. The
latter possibility appears to be ruled out by Lee et al. (1989 )
who reported an inhibitory effect of TPA on oestrogen recep-
tor levels in MCF-7 cells. This reduction in oestradiol recep-
tor levels may contribute to an explanation of the ability of
TPA to block the stimulation of growth by oestradiol in
MCF-7 cells.
The inhibitory action of TPA on MCF-7 cells is well
documented and it has been suggested that part of the action
of TPA may be attributed to its ability to activate protein
kinase C, which leads to phosphorylation of the EGF-
receptor and a resultant acute decrease in binding affinity (Lee
et al., 1989). However, these same changes in EGF-receptor
function are also observed in systems for which TPA has a
growth stimulatory effect, such as Swiss 3T3 cells (Brooks &
Brooks, 1990). Thus the role of the EGF-receptor in growth
inhibition of MCF-7 cells by TPA is equivocal.
An additional possibility examined to explain the growth
inhibition of MCF-7 cells by TPA and bryostatin, was that
these agents might be stimulating the expression of TGF-il,
acting as an autocrine growth inhibitory factor. TGF-P1I
peptide has been shown to be produced by MCF-7 cells and
to be hormonally regulated in this cell line (Knabbe et al.,
1987). TGF-P1 has been reported to be reduced in MCF-7
cells treated with oestradiol (Dickson et al., 1986) and we
have confirmed this observation in our study. In addition, we
found treatment with TPA increased TGF-P1 mRNA, consis-
tent with the autocrine growth inhibition hypothesis. The
presence of functional TPA response elements in both the 5'
and, more unusually, the 3' regions of the human TGF-P1
gene is consistent with these observations (Kim et al., 1989;
Scotto et al., 1990). Furthermore, the combined effect of
oestradiol and TPA produced a marked increase in TGF-P11
mRNA, above that seen with TPA alone, even though oest-
radiol alone led to a reduction of TGF-P1 mRNA levels.
Bryostatin did not have a similar effect on TGF-P1 expres-
sion, producing only a small increase in TGF-,B mRNA with
no further effect when combined with oestradiol. Thus TPA
and bryostatin appear to have overlapping but also different
effects on these and other cells.
Although we observed that treatment of MCF-7 cells with
TPA and combinations of TPA and oestradiol increased the
level of TGF-P1 mRNA, the ability of TGF-PI to inhibit
MCF-7 cell growth is not clear, since conflicting reports
appear in the literature. Zugmaier et al. (1989) have com-
pared the effect of TGF-P on both early (<100) and late
passage (>500) MCF-7 cells and found growth inhibition
only in the former, attributing the lack of growth inhibition
in late passage cells to loss of TGF-P receptors. In our
studies late passage (>300) cells were used and we were also
unable to find any evidence of growth inhibition with
exogenous TGF-P (data not shown). However, it is still not
possible for us to reject the autocrine growth inhibition loop
hypothesis, since it may be that the effect of TPA is 2-fold,
with not only an increase in TGF-P expression but also the
induction of a necessary upregulation of TGF-P receptor
expression. Without the latter the effect of exogenous TGF-P
may not be manifested. Only low numbers of TGF-P recep-
tors have been found in MCF-7 cells (Arteaga et al., 1988;
Guerrin et al., 1990). TPA may have the effect of increasing
TGF-P receptors to the level at which the cells become
responsive to the growth inhibitory effect of the
concort,itantly elevated TGF-P expression. Such a 2-fold
autocrine inhibitory mechanism has been implicated in the
TPA-induced growth inhibition of other cell types (Sing et
al., 1990; Takaishi et al., 1990). The possibility of a similar
mechanism operating in MCF-7 and other tumour cells
which are growth inhibited by TPA and other protein kinase
C activators merits further investigation.
Bryostatin is due to enter phase I clinical trials. The ability
of bryostatin to both mimic and antagonise the effects of
TPA suggests that it has both similar and different interac-
tions with protein kinase C compared with TPA. Our results
indicate that the response of breast tumours to bryostatin
will vary and it seems likely this will depend on the growth
signal transduction pathway status of individual tumours.
Further studies are required to establish tests which will
identify tumours likely to respond to agents which interact
with protein kinase C.
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